# EDGAR Filing Document

**Accession Number:** 0001403708
**File Stem:** 0001193125-25-263553
**Filing Date:** 2025-11
**Character Count:** 23740
**Document Hash:** 7e86a218c34b1dceac5851e6cd1f0fee
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-263553.hdr.sgml**: 20251104

**ACCESSION NUMBER**: 0001193125-25-263553

**CONFORMED SUBMISSION TYPE**: SC TO-C

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20251104

**DATE AS OF CHANGE**: 20251104

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Evoke Pharma Inc
- **CENTRAL INDEX KEY:** 0001403708
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 208447886
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-C
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-87872
- **FILM NUMBER:** 251447772

**BUSINESS ADDRESS:**
- **STREET 1:** 420 STEVENS AVENUE
- **STREET 2:** SUITE 230
- **CITY:** SOLANA BEACH
- **STATE:** CA
- **ZIP:** 92075
- **BUSINESS PHONE:** 858-345-1494

**MAIL ADDRESS:**
- **STREET 1:** 420 STEVENS AVENUE
- **STREET 2:** SUITE 230
- **CITY:** SOLANA BEACH
- **STATE:** CA
- **ZIP:** 92075
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** QOL Medical, LLC
- **CENTRAL INDEX KEY:** 0002093432

**ORGANIZATION NAME:**
- **EIN:** 743030385
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-C

**BUSINESS ADDRESS:**
- **STREET 1:** 3405 OCEAN DRIVE
- **CITY:** VERO BEACH
- **STATE:** FL
- **ZIP:** 32963
- **BUSINESS PHONE:** 866-469-3773

**MAIL ADDRESS:**
- **STREET 1:** 3405 OCEAN DRIVE
- **CITY:** VERO BEACH
- **STATE:** FL
- **ZIP:** 32963

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**SCHEDULE TO** 

**Tender Offer Statement Under Section 14(d)(1) or 13(e)(1)** 

**of the Securities Exchange Act of 1934** 

## EVOKE PHARMA, INC.
**(Name of Subject Company (Issuer))** 

**QOL-EOS MERGER SUB, INC.** 

**(Offeror)** 

**a direct wholly owned subsidiary of** 

**QOL MEDICAL, LLC** 

**(Offeror)** 

**(Name of Filing Persons (identifying status as offeror, issuer or other person))** 

**Common Stock, $0.0001 par value** 

**(Title of Class of Securities)** 

**30049G302** 

**(CUSIP Number of Class of Securities)** 

**Matthew L. Wotiz** 

**QOL Medical, LLC** 

**3405 Ocean Drive** 

**Vero Beach, Florida 32963** 

**(866) 469-3773** 

**(Name, Address, and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)** 

***With Copies to*:** 

**John C. Connery Jr.** 

**Roland S. Chase** 

**Hill Ward Henderson** 

**101 E. Kennedy Blvd., Suite 3700** 

**Tampa, Florida 33602** 

**(813) 221-3900** 

☒ Check the box if the filing relates solely to preliminary communications made before the commencement of a
tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;☒ Third-party tender offer subject to Rule 14d-1.

☐ Issuer tender offer subject to Rule 13e-4.

☐ Going-private transaction subject to Rule 13e-3.

☐ Amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer: ☐

If applicable, check the appropriate box(es) below to designate the appropriate rule provisions relied upon:

☐ Rule 13e-4(i) (Cross-Border Issuer Tender Offer).

☐ Rule 14d-1(d) (Cross-Border Third-Party Tender Offer).

------

The pre-commencement communication filed under cover of this tender offer statement on Schedule TO is being filed by QOL Medical, LLC, a Delaware limited liability company (the "**Parent**"), and QOL-EOS Merger Sub, Inc., a Delaware corporation (the "**Purchaser**"), a direct wholly-owned subsidiary of the Parent, in connection with a planned tender offer by Purchaser for all of the outstanding shares of common stock, par value $0.0001 (the "**Shares**"), of Evoke Pharma, Inc., a Delaware corporation (the "**Company**"). The planned tender offer and the related merger will be effected pursuant to an Agreement and Plan of Merger, dated as of November 3, 2025, by and among Parent, Purchaser and the Company (the "**Merger Agreement**").

**Important Information about the Tender Offer** 

The tender offer referenced in this document, including any and all exhibits attached to this document (collectively, this "**Communication**"), has not yet commenced. This Communication is neither an offer to purchase nor a solicitation of an offer to sell any Shares or any other securities. The offer and solicitation with respect to the Shares will only be made pursuant to a tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and other related materials that the Parent and the Purchaser intend to file with the U.S. Securities and Exchange Commission ("**SEC**"). In addition, the Company will file with the SEC a solicitation/recommendation statement on Schedule 14D-9 (the "**Solicitation/Recommendation Statement**") with respect to the tender offer. Those materials and all other documents filed by, or caused to be filed by, the Parent, the Purchaser and the Company with the SEC will be available at no charge on the SEC's website at www.sec.gov or by directing requests to the information agent for the offer, which will be named in the offer to purchase. Investors may also obtain, at no charge, any such documents filed with or furnished to the SEC by the Company on the Company's website at https://evokepharma.com/.

**INVESTORS AND SECURITY HOLDERS ARE URGED TO READ, CAREFULLY AND IN THEIR ENTIRETY, BOTH THE TENDER OFFER MATERIALS (INCLUDING THE OFFER TO PURCHASE, LETTER OF TRANSMITTAL AND RELATED DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT REGARDING THE TENDER OFFER, AS THEY EACH MAY BE AMENDED FROM TIME TO TIME, WHEN THEY BECOME AVAILABLE AND PRIOR TO MAKING ANY DECISIONS WITH RESPECT TO WHETHER TO TENDER THEIR SHARES IN THE TENDER OFFER BECAUSE THEY CONTAIN IMPORTANT INFORMATION, INCLUDING THE TERMS AND CONDITIONS OF THE TENDER OFFER.** 

**Cautionary Note Regarding Forward-Looking Statements** 

Statements included in this Communication, including any and all of its exhibits, that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negatives of these terms or other similar expressions. The forward-looking statements are based on the Parent's current beliefs and expectations and include, but are not limited to: statements regarding the planned completion of the transactions contemplated by the Merger Agreement and the timing thereof and expectations regarding the benefits sought to be achieved in the transactions. Actual results may differ from those set forth in this Communication, perhaps materially so, due to the risks and uncertainties inherent in the proposed transactions and other risks and uncertainties, including, without limitation: uncertainties as to the timing and completion of the tender offer and the merger; uncertainties as to whether at least a majority of Company stockholders will tender their Shares in the tender offer; the possibility that the closing conditions for the tender offer or the merger may not be satisfied or waived; the possibility that competing offers or acquisition proposals will be made; the effects of disruption caused by the transactions and the impact of the announcement and pendency of the transactions on the Parent and/or the Company's businesses, including their relationships with employees, collaborators, vendors, business partners or governmental entities; risks related to diverting management's attention from ongoing business operations and opportunities; the risk that stockholder litigation in connection with the transactions contemplated by the Merger Agreement may result in significant costs of defense, indemnification and liability; the risk that the offer or the merger may be more expensive to complete than anticipated; and other risks and uncertainties pertaining to the Parent's and the Company's business, including the risks and uncertainties detailed in the Company's prior press releases and in the periodic reports it files with the SEC, as well as the tender offer materials to be filed by the Parent and the Purchaser and the Solicitation/Recommendation Statement to be filed by the Company in connection with the tender offer.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Parent, the Purchaser and the Company undertake no obligation to revise or update these statements to reflect events or circumstances after the date hereof, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

------

**EXHIBIT INDEX** 

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release](d848429dex991.htm) |

---

## Exhibit 99.1

**Exhibit 99.1** 

---

| | |
|:---|:---|
| ![LOGO](g48107dsp1bbb.jpg) | ![LOGO](g48107dsp1aaa.jpg) |

---

**Evoke Pharma Enters into Definitive Agreement to Be Acquired by QOL Medical** 

*QOL Medical to Acquire All Outstanding Shares of Evoke for $11.00 Per Share in Cash* 

*Represents a 139.7% premium to most recent Nasdaq closing price* 

*Transaction expected to close by the end of 2025* 

SOLANA BEACH, Calif., and VERO BEACH, Fl., November 4, 2025 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ: EVOK) ("Evoke"), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI<sup>®</sup> (metoclopramide) nasal spray, and QOL Medical, LLC ("QOL Medical"), a privately held biopharmaceutical company specializing in treatments for GI and rare diseases, today announced that they have entered into a definitive agreement pursuant to which QOL Medical will acquire Evoke for $11.00 per share in cash at closing. The transaction has been unanimously approved by the Boards of Directors of both companies and will be conducted via a tender offer.

The transaction, expected to close by the end of 2025, reflects the strategic value of its commercial product, GIMOTI<sup>®</sup>, the first and only FDA-approved nasal spray formulation of metoclopramide for the treatment of acute and recurrent diabetic gastroparesis in adults. The purchase price represents a premium of 139.7% to Evoke's closing share price on November 3, 2025.

"Since inception, Evoke has remained singularly focused on serving the diabetic gastroparesis community by developing and delivering a new treatment option for a historically underserved population," said Matt D'Onofrio, Founder and Chief Executive Officer of Evoke. "This transaction recognizes the importance of what we've built, a differentiated, patient-centered therapy with a growing commercial presence. QOL Medical brings strong commercial GI experience, manufacturing capabilities, and a commitment to continuity, making them an ideal partner for the next chapter of our mission."

"We are excited about the strategic alignment between QOL and Evoke," said Derick Cooper, Chief Executive Officer of QOL Medical. "Evoke has developed an innovative therapy that addresses a significant unmet need in gastrointestinal care, offering meaningful clinical benefits for patients. GIMOTI strengthens our GI portfolio and advances our mission to support patients living with rare and underserved gastrointestinal conditions."

------

---

| | |
|:---|:---|
| ![LOGO](g48107dsp1bbb.jpg) | ![LOGO](g48107dsp1aaa.jpg) |

---

"With our deep experience in commercializing treatments for GI disorders, this acquisition is a natural extension of our capabilities and commitment", Cooper added. "It enables us to build on our existing infrastructure, expand our reach among patients and healthcare providers, and further establish QOL Medical as a leader in specialty gastrointestinal care."

**Transaction Terms** 

Under the terms of the merger agreement, QOL Medical, through a subsidiary, will initiate a tender offer to acquire all outstanding shares of Evoke at a price of $11.00 per share in cash at closing. The closing of the tender offer will be subject to certain conditions, including the tender of at least a majority of the outstanding shares of Evoke at such time, and other customary closing conditions. Upon the successful completion of the tender offer, a subsidiary of QOL Medical will merge into Evoke and any remaining shares of common stock of Evoke will be cancelled and converted into the right to receive the same price per share payable in the tender offer.

The transaction is not subject to a financing condition and QOL Medical intends to finance the transaction using cash on hand. The transaction is expected to close in the fourth quarter of 2025, subject to the terms of the merger agreement.

**Advisors** 

Stifel is acting as exclusive financial advisor and Latham & Watkins is serving as legal counsel to Evoke. Hill Ward Henderson is serving as legal counsel to QOL Medical.

**About QOL Medical, LLC** 

QOL Medical is a specialty biopharmaceutical company committed to delivering solutions for rare diseases. Founded in 2003, QOL Medical focuses on improving clinical outcomes and enhancing the quality of life for patients with rare diseases through the acquisition and commercialization of orphan and gastrointestinal products in underserved markets. Learn more at **<u>www.qolmed.com</u>**.

**About Evoke Pharma, Inc.** 

Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.

------

---

| | |
|:---|:---|
| ![LOGO](g48107dsp1bbb.jpg) | ![LOGO](g48107dsp1aaa.jpg) |

---

Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis.

Visit <u>www.EvokePharma.com</u> for more information.

Follow Evoke Pharma on <u>LinkedIn</u>

Follow Evoke Pharma on <u>Twitter</u>

**About Gimoti<sup>®</sup> (metoclopramide) nasal spray** 

GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Important Safety Information:

WARNING: TARDIVE DYSKINESIA

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Metoclopramide can cause tardive dyskinesia (TD), a serious movement disorder that is often irreversible. The risk of
developing TD increases with duration of treatment and total cumulative dosage.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Discontinue GIMOTI in patients who develop signs or symptoms of TD. In some patients, symptoms may lessen or resolve after
metoclopramide is stopped.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Avoid treatment with metoclopramide (all dosage forms and routes of administration) for longer than 12 weeks because of the
increased risk of developing TD with longer-term use *.* 

GIMOTI is not recommended for use in:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the
risk of methemoglobinemia in neonates *.* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Moderate or severe hepatic impairment (Child-Pugh B or C), moderate or severe renal impairment (creatinine clearance less
than 60 mL/minute), and patients concurrently using strong CYP2D6 inhibitors due to the risk of increased drug exposure and adverse reactions.

GIMOTI is contraindicated:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In patients with a history of tardive dyskinesia (TD) or a dystonic reaction to metoclopramide.

------

---

| | |
|:---|:---|
| ![LOGO](g48107dsp1bbb.jpg) | ![LOGO](g48107dsp1aaa.jpg) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• When stimulation of gastrointestinal motility might be dangerous (e.g., in the presence of gastrointestinal hemorrhage
mechanical obstruction, or perforation).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In patients with pheochromocytoma or other catecholamine-releasing paragangliomas. Metoclopramide may cause a
hypertensive/pheochromocytoma crisis, probably due to release of catecholamines from the tumor.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In patients with epilepsy. Metoclopramide may increase the frequency and severity of seizures.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In patients with hypersensitivity to metoclopramide. Reactions have included laryngeal and glossal angioedema and
bronchospasm.

Potential adverse reactions associated with metoclopramide include: Tardive dyskinesia (TD), other extrapyramidal effects (EPS), parkinsonism symptoms, motor restlessness, neuroleptic malignant syndrome (NMS), depression, suicidal ideation and suicide, hypertension, fluid retention, hyperprolactinemia, effects on the ability to drive and operate machinery. Most common adverse reactions (≥5%) for GIMOTI are: dysgeusia, headache, and fatigue. These are not all of the possible side effects of GIMOTI. Call your doctor for medical advice about whether you should take GIMOTI and the possible risk factors and side effects. You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit <u>www.fda.gov/medwatch</u> or call 1-800-FDA-1088.

**Additional Information and Where to Find It** 

The tender offer described above has not yet commenced. This communication is not an offer to buy nor a solicitation of an offer to sell any securities of Evoke. The solicitation and the offer to buy shares of Evoke's common stock will only be made pursuant to a tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and other related materials that QOL Medical and its acquisition subsidiary ("Merger Sub") intend to file with the U.S. Securities and Exchange Commission ("SEC"). In addition, Evoke will file with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the tender offer. Once filed, investors will be able to obtain a free copy of these materials and other documents filed by QOL Medical, Merger Sub and Evoke with the SEC at the website maintained by the SEC at www.sec.gov. Investors may also obtain, at no charge, any such documents filed with or furnished to the SEC by Evoke on Evoke's website at https://evokepharma.com/. INVESTORS AND SECURITY HOLDERS ARE ADVISED TO READ THESE DOCUMENTS WHEN THEY BECOME AVAILABLE, INCLUDING THE TENDER OFFER MATERIALS OF QOL MEDICAL AND MERGER SUB AND THE SOLICITATION/RECOMMENDATION STATEMENT OF EVOKE, IN EACH CASE INCLUDING

------

---

| | |
|:---|:---|
| ![LOGO](g48107dsp1bbb.jpg) | ![LOGO](g48107dsp1aaa.jpg) |

---

ANY AMENDMENTS THERETO, AS WELL AS ANY OTHER DOCUMENTS RELATING TO THE TENDER OFFER AND THE MERGER THAT ARE FILED WITH THE SEC, CAREFULLY AND IN THEIR ENTIRETY PRIOR TO MAKING ANY DECISIONS WITH RESPECT TO WHETHER TO TENDER THEIR SHARES INTO THE TENDER OFFER BECAUSE THEY CONTAIN IMPORTANT INFORMATION, INCLUDING THE TERMS AND CONDITIONS OF THE TENDER OFFER.

**Forward-Looking Statements** 

Evoke, QOL Medical and Merger Sub caution you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negatives of these terms or other similar expressions. The forward-looking statements are based on the parties' current beliefs and expectations and include, but are not limited to: statements regarding the planned completion of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement") and the timing thereof; expectations regarding the benefits sought to be achieved in the transactions; the continued commercial availability of GIMOTI; the continuation of Evoke's partnership with Eversana; and QOL Medical's strategic vision. The inclusion of forward-looking statements should not be regarded as a representation by Evoke, QOL Medical or Merger Sub that any of their respective plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoke's and QOL Medical's businesses and the proposed transactions, including, without limitation: uncertainties as to the timing and completion of the tender offer and the merger; uncertainties as to the percentage of Evoke stockholders tendering their shares in the tender offer; the possibility that competing offers will be made; the possibility that various closing conditions for the tender offer or the merger may not be satisfied or waived; the effects of disruption caused by the transaction making it more difficult to maintain relationships with employees, collaborators, vendors and other business partners; risks related to diverting management's attention from the parties' ongoing business operations; the risk that stockholder litigation in connection with the transactions contemplated by the Merger Agreement may result in significant costs of defense, indemnification and liability; potential changes in QOL Medical's strategic vision; and other risks and uncertainties pertaining to Evoke's business, including the risks and uncertainties detailed in Evoke's prior press releases and in the periodic reports it files with the SEC, as well as the tender offer materials to be filed by QOL Medical and Merger Sub and the Solicitation/Recommendation Statement to be filed by Evoke in connection with the tender offer.

------

---

| | |
|:---|:---|
| ![LOGO](g48107dsp1bbb.jpg) | ![LOGO](g48107dsp1aaa.jpg) |

---

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and none of Evoke, QOL Medical or Merger Sub undertake any obligation to revise or update these statements to reflect events or circumstances after the date hereof, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

**Investor & Media Contact for Evoke Pharma:**

Daniel Kontoh-Boateng

DKB Partners

Tel: 862-213-1398

<u>dboateng@dkbpartners.net</u>

**Investor & Media Contact for QOL Medical:** 

Chelsea King

QOL Medical, LLC

Tel: 866-469-3773 x1091

<u>cking@qolmed.com</u>